Kimberly Noonan, NP

home / authors / kimberly-noonan-np

Articles

$Tailoring Treatment for Multiple Myeloma Patients With Relapsed and Refractory Disease$

Tailoring Treatment for Multiple Myeloma Patients With Relapsed and Refractory Disease

Paul G. Richardson, MD;Jacob Laubach, MD;Constantine S. Mitsiades, MD, PhD;Robert L. Schlossman, MD;Deborah Doss, BSN, RN;Kathleen Colson, RN;Mary L. Mckenney, NP;Kimberly Noonan, NP;Irene M. Ghobrial, MD;Nikhil C. Munshi, MD;Kenneth C. Anderson, MD

March 16th 2010

Responses to treatment of relapsed and refractory multiple myeloma are characteristically short, and median survival is as brief as 6 months. Although prognostic factors in the context of relapsed and refractory disease require further characterization, high-risk patients include those with certain cytogenetic abnormalities, high β2-microglobulin, and low serum albumin.